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 Abstract
Flow cytometry specializes in high-content measurements of cells and particles in sus-
pension. Having long excelled in analytical throughput of single cells and particles, only
recently with the advent of HyperCyt sampling technology, flow cytometry’s multiex-
periment throughput has begun to approach the point of practicality for efficiently ana-
lyzing hundreds-of-thousands of samples, the realm of high-throughput screening
(HTS). To extend performance and automation compatibility, we built a HyperCyt-
linked Cluster Cytometer platform, a network of flow cytometers for analyzing samples
displayed in high-density, 1,536-well plate format. To assess the performance, we used
cell- and microsphere-based HTS assays that had been well characterized in the previ-
ous studies. Experiments addressed important technical issues: challenges of small wells
(assay volumes 10 lL or less, reagent mixing, cell and particle suspension), detecting
and correcting for differences in performance of individual flow cytometers, and the
ability to reanalyze a plate in the event of problems encountered during the primary
analysis. Boosting sample throughput an additional fourfold, this platform is uniquely
positioned to synergize with expanding suspension array and cell barcoding technolo-
gies in which as many as 100 experiments are performed in a single well or sample. As
high-performance flow cytometers shrink in cost and size, cluster cytometry promises
to become a practical, productive approach for HTS, and other large-scale investiga-
tions of biological complexity. ' 2012 International Society for Advancement of Cytometry
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INTRODUCTION
Microscope imaging-based high-content screening (HCS) platforms revolutio-
nized the drug discovery enterprise when introduced in the late 1990s, bridging the
gap between throughput and information richness of experiments performed with
adherent cells (1). Imaging-based HCS technology has improved and expanded over
subsequent years to become considered a mainstream screening technology in the
pharmaceutical industry (2). Flow cytometry is a complementary technology that
specializes in high-content measurements of suspension cells such as leukocytes and
hematopoetic stem cells. It measures multiple optical signals associated with cells or
particles as they pass through a laser-based detection system, one at a time. Flow
cytometry has long excelled in throughput and information density for the analysis
of individual cells, now routinely capable of quantifying 16 or more features per cell
at tens-of-thousands of cells per second. However, only recently with the introduc-
tion of HyperCyt sampling technology it has begun to achieve levels of multiexperi-
ment throughput compatible with its application in a high-throughput screening
(HTS) environment (3–5).
HyperCyt uses a peristaltic pump in combination with an autosampler to boost
throughput of experimental samples 10- to 20-fold (3). The autosampler moves a
sample uptake probe from well to well of a multiwell microplate, whereas the con-
tinuously running pump causes uptake of a 1–2 lL sample from each well and an air
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bubble to separate each sample from the other. Samples from
all wells of a microplate are delivered to the flow cytometer in
a single round of analysis and stored in a single data file. Spe-
cialized software distinguishes and extracts data for individual
samples by virtue of temporal gaps in the flow of cells, result-
ing from passage of the sample-separating air bubbles through
the laser beam.
The platform has been extensively validated for produ-
cing high content, quantitative measurements while process-
ing 384-well plates in 11 min or less (6–20). It has been suc-
cessfully used in small-molecule screening assays to produce
more than 10 million experimental measurements of small
molecule interactions with biological targets, all published on
the publically accessible PubChem website (www.ncbi.nlm.-
nih.gov/pcassay). The conventional HyperCyt platform, of
which there are currently more than 100 in laboratories world-
wide, is linked to a single flow cytometer and typically pro-
cesses  15,000 wells/day. To achieve throughput compatible
with screening of libraries containing several hundred thou-
sand compounds or more, it has been necessary to use up to
four separate platforms running in parallel. This is an expen-
sive and labor-intensive approach that requires significant
institutional space and complex logistics of operation that are
not readily amenable to full automation. To improve perform-
ance efficiency and automation compatibility, we built and
tested a Cluster Cytometer HyperCyt platform that is capable
of analyzing samples displayed in high-density, 1,536-well
plate format.
MATERIALS AND METHODS
Cells and Reagents
Myeloid U937 cells transfected with the human formyl-
peptide receptor (FPR) were cultured in RPMI-1640 medium
(Mediatech, Manassas, VA; 15-041-CV) supplemented with
10% heat-inactivated fetal bovine serum (GIBCO, Grand
Island, NY; 14160), 2 mM L-glutamine-10 U/mL penicillin-10
lg/mL streptomycin (Omega Scientific, Tarzana, CA; PG-30),
10 mM HEPES (Sigma, St. Louis, MO; H-0887), and 4 lg/mL
Ciproflaxin (Mediatech MT61-277-RF). Cultures were grown
at 378C in a 5% CO2 atmosphere, and passaged every 3 days.
U937 cells were used that expressed a mutant FPR with glycine
and alanine substituted for serine and threonine residues in
the C-terminal tail (DeltaST) to prevent receptor internaliza-
tion (21). Peptide dilution buffer (PDB) consisted of 110 mM
NaCl (Sigma S-9625), 30 mM HEPES, 10 mM KCl (Sigma P-
3911), 1 mM MgCl2 (Sigma M-8266), 10 mM glucose (Sigma
G-8270), and 0.1% bovine serum albumin (Sigma B-2518).
Protease buffer consisted of 50 mM HEPES, 100 mM NaCl, 1
mg/mL bovine serum albumin, 0.025% Tween-20 (Sigma P-
7949), pH 7.4. N-formyl-methionine-leucine-phenylalanine-
phenylalanine peptide (fMLFF) was obtained from Sigma (F-
3506). Fluorescein-labeled tryptophan–lysine–tyrosine–methi-
onine–valine–D-methionine (WPEP–FITC) was obtained from
New England Peptide (Gardner, PA; custom synthesis) and
was previously characterized (22). Multiplexed sets of strepta-
vidin-coated microspheres were obtained from Spherotech
(Lake Forest, IN; Blue array particle kit, 5.1 lm, SVPAK500-
5067-X-4). Quantum FITC molecules of equivalent soluble
fluorescein (MESF) low-level and high-level fluorescein cali-
bration standard microspheres were obtained from Bangs Lab-
oratories (Fishers, IN; 824B and 825B, respectively). Recombi-
nant Bacillus anthracis lethal factor (LF) and Clostridium botu-
linum neurotoxin light chain A (BoNTALC) were obtained
from List Laboratories (Campbell, CA; 169A and 610A,
respectively). All test compounds were stored in 100% DMSO
(Fisher Scientific, Fair Lawn, NJ; D136-1) and diluted 1:100 in
each assay so that wells containing test compounds also con-
tain 1% DMSO. Control wells are added with 1% DMSO (ve-
hicle control) to control for potential extraneous effects of
DMSO on the assay. A key aspect of assay development is
demonstration that the assay output is unaffected by DMSO
in amounts expected to be present in test compound contain-
ing wells.
Hardware and Software
Accuri C6 flow cytometers equipped with CFlow Plus
and CFlow Plus Automation software were obtained from
BDAccuri (Ann Arbor, MI). All had the standard configura-
tion of detectors common to most if not all other C6s. Photo-
multiplier tubes and other detectors were operated at fixed,
manufacturer-specified voltages and gains that were not sub-
jected to user modification. The GX274 autosampler and
4-channel peristaltic pump were obtained from Gilson Instru-
ments (Middleton, WI). HyperCyt Autosampler control soft-
ware (version 2.0, IntelliCyt, Albuquerque, NM) was modified
to control the GX274 autosampler and Accuri C6 flow cyt-
ometers via RS232 serial port and Ethernet TCP/IP network
communication, respectively. HyperView software (version
2.5.1, IntelliCyt) was modified to enable linked analysis of the
four FCS data files generated by processing of each 1,536-well
plate and automated standardization of fluorescence data
from curves generated with fluorescein calibration standard
microspheres. A Biomek FX robot (Beckman Coulter, India-
napolis, IN) equipped with a 1,536 pintool set containing 100
nL pins (V&P Scientific, San Diego, CA; VP 550A) was used
to transfer small molecule test compounds to 1,536-well bioas-
say plates. A MicroFlo Select dispenser equipped with a 1-lL
dispense cassette (BioTek Instruments, Winooski, VT) was
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used to dispense cells, microspheres, and reagents into wells.
Assays were performed in 1,536-well, HiBase polystyrene
plates (MPG-782101; Greiner Bio-One, Monroe, NC).
FPR Ligand-Binding Inhibition Assay
As described previously (23,24), the FPR assay measures
the ability of test compounds to compete with a high-affinity
fluorescent ligand, WPEP–FITC, for binding to cell membrane
FPR. The assay response was quantified on the basis of median
green fluorescence intensity (MFI) determinations of cell-
bound WPEP–FITC made for individual wells. The assay
response range was defined by replicate control wells contain-
ing unlabeled fMLFF blocking peptide in PDB (positive con-
trols, with minimum MFI expected from complete inhibition
of WPEP–FITC binding) or PDB with 1% DMSO alone
(negative controls, with maximum MFI expected from no in-
hibition of WPEP–FITC binding). For assay performance,
additions to wells were in sequence as follows: (1) 375 nM
fMLFF or PDB alone (4 lL/well); (2) cells (107/mL, 3 lL/
well); (3) (after 30 min, 48C incubation) 17 nM WPEP–FITC
(3 lL/well). After an additional 45 min, 48C incubation, plates
were immediately analyzed by flow cytometry with the
HyperCyt
1
platform. All incubations were performed with
plates rotating continuously from inverted to upright position
to maintain cells in suspension. Test compound inhibition of
WPEP–FITC binding to FPR was calculated as 100 3
(MFIMAX 2 MFITEST)/(MFIMAX 2 MFIMIN), in which
MFIMAX and MFIMIN represent the averages for MFI determi-
nations in negative and positive control wells, respectively, and
MFITEST represents the MFI measured in wells containing test
compounds and WPEP–FITC in combination. Details of gat-
ing strategy and an assay schematic are shown in Supporting
Information Fig. 3.
Protease Inhibition Assay
Protease inhibition assays were performed as described
previously (25), but with modifications. Biotinylated green
fluorescent protein (GFP) protease substrates for LF, BoN-
TALC, and a protease-resistant substrate (pinpointGFP)
were prepared and loaded on streptavidin microspheres as
described previously (14,25,26). Additions to wells were in
sequence as follows: (1) 4 lL protease buffer; (2) 2 lL of a
mixture of 1.5 lM LF and 5 nM BoNTALC in protease
buffer; (3), 100 nL of test compounds (1 mM in DMSO);
and (4) 4 lL containing 2 3 105/mL of each set of sub-
strate-bearing microspheres. Plates were sealed and incu-
bated at 248C overnight (16–18 h), rotating continuously
from inverted to upright position until analyzed in the
HyperCyt platform the following day. The assay response
was quantified on the basis of MFI determinations of micro-
sphere-bound protease substrate-GFP made for individual
wells. The assay response range was defined by replicate
control wells containing no proteases (positive controls, with
maximum MFI reflecting the expected response from com-
plete protease inhibition) or the protease mixture alone
(negative controls, with minimum MFI reflecting complete
absence of protease inhibition). Test compound inhibition
of substrate cleavage by protease resulted in an increase in
MFI relative to negative controls and was calculated as 100
3 (MFITEST 2 MFIMIN)/(MFIMAX 2 MFIMIN), in which
MFIMIN and MFIMAX represent the averages for MFI deter-
minations in negative and positive control wells, respectively,
and MFITEST represents the MFI measured in wells contain-
ing test compounds and protease mixtures in combination.
Details of gating strategy and an assay schematic are shown
in Supporting Information Fig. 4.
G Protein-Coupled Receptor Kinase 2 Assay
The G protein-coupled receptor kinase 2 (GRK2) assay
measures the ability of test compounds to displace a fluor-
escently labeled RNA aptamer that binds with nanomolar
affinity to the GRK2 protein. GRK2 protein was biotinyl-
ated using biotin N-hydroxysuccinimide ester (Sigma) and
conjugated to streptavidin-coated beads (Spherotech) at 48C
overnight in GRK2 assay buffer (20 mM HEPES, pH 7.0,
10 mM NaCl, 5 mM MgCl2, 0.1% Lubrol, 2 mM DTT, 1
mM CHAPS). The RNA aptamer was fluorescently labeled
at a single site on the 30 end with 6-carboxyfluorescein to
produce aptamer-30-FAM (1 FAM group per RNA aptamer,
synthesized, and labeled by IDT (www.IDTDNA.com)),
which was diluted to 6.6 nM in GRK2 assay buffer. A total
volume of 10 lL was added to wells in the following
sequence: (1), 4 lL GRK2 assay buffer; (2), 100 nL of 1
mM test compounds; (3), 3 lL GRK2-conjugated beads,
incubated at room temperature for 15 min; and (4), 3 lL
6.6 nM aptamer-30-FAM. Plates were incubated at room
temperature for 1 h, rotating continuously from inverted to
upright position. Plates were then analyzed by flow cytome-
try with the HyperCyt platform. The assay response was
quantified on the basis of aptamer-30-FAM MFI determina-
tions made for individual wells. The assay response range
was defined by replicate control wells containing 1%
DMSO vehicle control (negative controls, with maximum
MFI expected from no inhibition of aptamer-30-FAM bind-
ing) or 503 unlabeled RNA aptamer in assay buffer (posi-
tive controls, with minimum MFI expected from complete
inhibition of aptamer-30-FAM binding). Test compound in-
hibition of aptamer-30-FAM binding to GRK2 was calcu-
lated as 100 3 (MFIMAX 2 MFITEST)/(MFIMAX 2 MFIMIN)
in which MFIMAX and MFIMIN represent the averages for
MFI determinations in negative and positive control wells,
respectively, and MFITEST represents the MFI measured in
wells containing test compounds and aptamer-30-FAM in
combination.
Assay Quality Assessment
In all assays, the mean and standard deviation (SD) of
MFI measurements from replicate control wells were used to
calculate the Z0 score, a dimensionless measure of screening
assay quality that reflects both assay signal dynamic range and
data variation associated with the signal measurements (27).
As illustrated in assay descriptions above, some assays were
designed to detect test compound effects that cause an
increase in MFI, whereas others were designed to detect MFI
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decreases. Positive control wells represented the maximum
expected MFI in the former case, the minimum in the latter,
and vice-versa for negative control wells. For the purposes
of calculating Z0, the important consideration was only that
control wells with minimum and maximum MFI be distin-
guished as follows:
Z 0 ¼1fð½33SDMAX þ ½33SDMIN=ðMeanMAX MeanMINÞg
where MeanMAX and SDMAX represent the mean and SD of MFI
values from control wells with maximum MFI, and MeanMIN
and SDMIN are the same for control wells with minimum MFI.
Possible values of Z0 range from negative infinity to 1.0. An assay
is deemed excellent for screening purposes if Z0 is in the range
between 0.5 and 1.0. A Z0 value of 0 is indicative of a screening
assay capable of providing only a ‘‘yes/no’’ type of output.
An alternative statistic is the Z-factor, which is calculated
in a similar fashion as Z0 except that (1) the terms in the equa-
tion pertaining to the negative control wells are substituted
with mean and SD MFI values for all wells in the plate exclud-
ing the positive control wells and (2) the absolute value of the
difference term in the denominator is used. The Z-factor is
subject to influence from a variety of additional factors that
do not affect Z0 such as compound concentration and number
of active compounds on the plate. As the value of Z0 is subject
to fewer nuances of interpretation than the Z-factor, we exclu-
sively used Z0 for the purposes of evaluating instrument per-
formance in the present studies.
Flow Cytometry
All analyses were performed with Accuri C6 flow cyt-
ometers (see above). Singlet populations of cells and micro-
spheres were selectively gated for the analysis on the basis of
forward light scatter (linear scale) and side light scatter (log
scale) from a 488-nm laser. Green fluorescence emission
detected at 533/30 nm was excited by a 488-nm laser, recorded
in the FL1-H channel, and displayed in log scale. Red fluores-
cence emission detected at 675/25 was excited by a 640-nm
laser, recorded in the FL4-H channel, and displayed in log
scale. Representative list mode and GatingML files for any of
the figures are available upon request from the corresponding
author.
RESULTS
Cluster Cytometry
The platform consisted of a high-precision positioning
autosampler, a cluster of four small-footprint, moderate-cost
Accuri C6 flow cytometers, and a four-channel peristaltic
pump that delivered samples from four sample uptake probes
to each of the flow cytometers (Fig. 1a and Supporting Infor-
mation Fig. 2). The cytometers were remotely controlled over
an Ethernet network by a netbook computer that coordinated
Figure 1. Cluster Cytometer HyperCyt Platform. (a) Schematic of the Cluster Cytometer HyperCyt platform illustrating sample transfer lines
linking sample uptake ports from each of four flow cytometers to sampling probes positioned above the 1,536-well plate (solid lines), and se-
rial (small dashed lines) and Ethernet network (large dashed lines) connections by which a netbook PC controls the autosampler and cyt-
ometers, respectively. (b) Close-up of the four sampling probes during processing of a 1,536-well plate. (c) Parallel sampling pattern from left
to right and top to bottom of the four 384-well segments of a 1,536-well plate, each segment analyzed by the indicated cytometer. (d) Histo-
gram of the red fluorescence distribution of five color-coded sets of microspheres representing pooled data from all wells and cytometers
collected from a 1,536-well plate. (e) Time-resolved display of five-plex microsphere data from 1,536-well plate analysis in which data from
each cytometer as indicated are linked together for display in a single plot (bottom). Although collected in parallel, data from each cytometer
are displayed side-by-side on a common Microplate Wells axis for better visual comparison. Zoomed-in 50-s plot sections (top,  30 wells
each) illustrate the uniformity of resolution by each cytometer of bead sets (red fluorescence intensity axis) and well content (gap-separated
clusters on the Microplate Wells axis) across the plate. Additional gating information is shown in Supporting Information Figure 2. [Color fig-
ure can be viewed in the online issue which is available at wileyonlinelibrary.com]
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autosampler and cytometer operation, file naming via barcode
reader, and data streaming to a centralized storage location
where data from the four cytometers were linked and analyzed
(Fig. 1a). To enable high-throughput analysis of samples dis-
played in 1,536-well plate format, the four sample uptake
probes were positioned at eight-well intervals across the 32-
row dimension of the plate (Fig. 1b). The autosampler moved
the 4-probe head across the 48-column plate dimension row-
by-row so that each probe sampled a 384-well segment of the
plate (Fig. 1c). In initial pilot tests, a multiplexed preparation
of microspheres consisting of five sets with distinctive red flu-
orescence intensity profiles (Fig. 1d) was dispensed into a
1,536-well plate so that each well contained 2,000 micro-
spheres from each set in a 10-lL volume. Approximately, 2 lL
was aspirated per well from each plate segment in parallel at a
rate that allowed the entire plate to be processed in\11 min.
In a representative experiment, each cytometer consistently
resolved the samples from individual wells as well as the five
discrete fluorescence profiles of microspheres in each sample
(Fig. 1e). The number of microspheres detected from each of
the five fluorescence intensity sets averaged from 299  34 to
328  31 per well over the entire plate and ranged from a min-
imum of 108 to a maximum of 429 from each set per well.
Cluster Cytometer Performance
Performance of the HyperCyt platform has been exten-
sively validated for both cell and microsphere based HTS
assays in 96- and 384-well format. However, the move to
1,536-well plates and use of multiple flow cytometers in paral-
lel accentuated several new technical issues: the need to restrict
assay volumes to 10 lL or less to accommodate smaller wells,
limited options for ensuring adequate mixing of reagents and
suspension of cells and particles in such small wells, the poten-
tial need to detect and correct for differences in the perform-
ance of individual flow cytometers, and the ability to reanalyze
a plate in the event of problems encountered with one or
more of the cytometers (e.g., clogging) during the primary
analysis. To address these issues, we used cell- and micro-
sphere-based HTS assays that had been well characterized in
the previous studies.
Figure 2. FPR ligand-binding assay analysis. U937 cells expressing FPR were incubated with green fluorescent FPR ligand (WPEP—FITC)
in the presence (positive control wells) or absence (negative control wells) of a nonfluorescent FPR ligand (fMLFF). (a) Plot of linked sam-
ples data from all cytometers. (b) Zoomed-in region illustrating the initial 10-s sampling of calibration standard microspheres (MESF stand-
ards) followed by sampling of microplate wells. Indicated are gap-separated samples from the first 48-well row in which the first 44 are
negative control wells, the next two are positive control wells, and the last two are rinse wells (no cells). (c) Scatter plot (forward and side
scatter from the 488-nm laser) of data pooled from all wells and cytometers illustrating electronic gates used to distinguish U937 cells
(ellipse in center) and calibration standards microspheres (top left circle). (d) Green fluorescence distribution of the calibration standards
microspheres from the four cytometers. Labels at top indicate the cytometer and at left the MESF corresponding to microsphere clusters
resolved on the FITC axis. A two-parameter dot-plot display was used to illustrate homogeneity of the microsphere populations. Red fluo-
rescence intensity was used as the x-axis parameter to demonstrate that there was little or no FITC fluorescence spillover into the red fluo-
rescence channel used to distinguish red fluorescent microsphere sets in Figures 1 and 3. (e) Log—Log plots of MESF vs. FITC green fluo-
rescence intensity of calibration standards microspheres recorded by each cytometer. Lines fitted by linear regression were used to trans-
form cell WPEP—FITC data from each well to calibrated MESF for the analysis reported in Table 1 and Supporting Information Figure 5.
Detailed gating information and a schematic illustrating the assay principles are shown in Supporting Information Figure 3. [Color figure
can be viewed in the online issue which is available at wileyonlinelibrary.com]
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Cell Suspension, Mixing, and Cross-cytometer
Fluorescence Response Calibration
The FPR ligand-binding inhibition assay, successfully
used to identify high-affinity, small-molecule FPR antagonists
(24,28), tests the ability of compounds to displace a fluores-
cent peptide ligand, WPEP–FITC, from FPRs expressed in
membranes of intact cells (23,29) (Supporting Information
Fig. 3d). The original assay volume of 15 lL was reduced to 10
lL by increasing cell and reagent concentrations. Three se-
quential rounds of droplet deposition with a microdispenser
were used to fill wells first with control solutions with or with-
out receptor blocking peptide ligand (4 lL), then cells (3 lL)
and finally, WPEP–FITC fluorescent ligand. All mixing in wells
was exclusively accomplished by rotating the plates end-over-
end from inverted to upright position at 4 rpm during each
incubation step as described previously (30). Plates were set
up with 44 wells of each row as negative controls (cells plus
WPEP–FITC to produce brightly fluorescent cells) and 2 as
positive controls (cells and WPEP–FITC plus excess nonfluor-
escent, blocking peptide ligand to produce dimly fluorescent
cells). The four sampling probes were programmed to aspirate
a suspension of fluorescein calibration standard microspheres
for 10 s prior to sampling of the 1,536-well plate. Thus, the
analysis results for each cytometer/plate segment had a cali-
bration standards fluorescence profile as an internal control of
cytometer fluorescence response performance (Figs. 2a and b).
The calibration standard microspheres had a distinctive light-
scattering profile (Fig. 2c) by which they could be distin-
guished from the cells and gated for separate analysis (Sup-
porting Information Figs. 3a–c). Comparison of the resulting
fluorescence calibration curve profiles for the four flow cyt-
ometers indicated a high degree of similarity (Figs. 2d and e).
In a representative plate, a greater than tenfold response
difference between positive and negative controls was observed
for each of the four cytometer/plate segments (Table 1). Z0
scores (27) calculated separately for each cytometer/plate seg-
ment on the basis of WPEP–FITC green fluorescence intensity
ranged from 0.579 to 0.819. When data from the four seg-
ments were pooled, as if the entire plate had been analyzed by
a single flow cytometer, the Z0 score was 0.704. Transformation
to a calibrated scale such as MESF is an accepted means of
normalizing data to compensate for differences between rela-
tive fluorescence response values produced by different flow
cytometers. Using regression coefficients from line fits shown
in Fig. 2d, calibrated MESF values were calculated for control
well data. Unexpectedly, such a transformation resulted in a
slightly lower Z0 score for pooled data (0.605) in association
with increased coefficients of variation (CVs) for positive and
negative controls (Table 1).
To further address this issue, we plotted calibrated MESF
values for both calibration microspheres and cells as a function
of nominal MESF for the four cytometers (Supporting Infor-
mation Fig. 5a). Calibrated MESF profiles and fitted regression
lines for the calibration microspheres were virtually identical
for all cytometers, an indication that the linear fit model
brought all cytometers into good quantitative agreement. By
contrast, the calibrated MESF values for cells from control
wells were less tightly grouped about the overlapping best fit
lines and showed relatively small but statistically significant
intercytometer differences within each control group. These
measurements were made on the basis of the height of the flu-
orescence pulse produced by cell or microsphere passage
through the laser beam (FL1-H). Such measurements can be
sensitive to differences in laser beam configuration between
cytometers (e.g., laser beam diameter), particularly when mak-
ing quantitative comparisons between particles of different
diameters as was the case for the microspheres and cells ( 5
vs.  9 lm, respectively). Therefore, we also investigated the
use of fluorescence pulse area measurements (FL1-A) that are
considered less sensitive to this potential source on intercyt-
ometer variation (Supporting Information Fig. 5b). Although
negative control values appeared to group more tightly in FL1-
A plots as compared to FL1-H plots, positive control values
did not exhibit a similar trend (Supporting Information Fig.
5b). It seems likely that plate position effects may have
accounted for some of the observed variations, perhaps reflect-
ing assay artifacts owing to edge effects or reagent dispensing
variation across the four quadrants of the 1536-well plate.
Taken together, these results suggested that the innate
variation between the four flow cytometers was relatively small
Table 1. Evaluation of the FPR fluorescent ligand-binding assay in 1536-well format
WPEP–FITC (MFI) CALIBRATED MESF
CYTOMETER CONTROLA MEAN SD CV Z0 MEAN SD CV Z0
1 Pos 2,080 96 4.6 0.579 10,390 492 4.7 0.572
Neg 22,378 2,750 12.3 120,176 15,183 12.6
2 Pos 2,140 64 3.0 0.819 8,544 265 3.1 0.815
Neg 23,067 1,199 5.2 100,825 5,428 5.4
3 Pos 2,032 44 2.2 0.819 9,350 207 2.2 0.816
Neg 23,522 1,254 5.3 114,534 6,240 5.4
4 Pos 1,895 100 5.3 0.704 8,108 437 5.4 0.699
Neg 23,130 1,998 8.6 105,542 9,324 8.8
All Pos 2,036 119 5.9 0.704 9,098 947 10.4 0.605
Neg 23,024 1,950 8.5 110,293 12,389 11.2
a Plate segments analyzed by each cytometer contained 352 negative control wells and 16 positive control wells.
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and subject to the sources of variation that could not be
improved by MESF transformation of fluorescence data.
Clearly documented was the importance of including assay
control wells in all plate quadrants and using fluorescence
data from them as the primary means for normalizing results
individually for each cytometer. The relative uniformity and
signal range of assay response values over the entire plate indi-
cated that adequate mixing had been accomplished without a
need for physical interventions such as pipetting or vortexing
of assay suspensions. This was confirmed by Z0 scores of 0.780,
0.781, and 0.830 that were obtained when three additional
plates were analyzed separately in a similar fashion (pooled
WPEP–FITC control well MFI data from the four segments of
each plate, data not shown).
Analysis Repeatability
We have previously described microsphere-based HTS
assays to detect the inhibitors of proteases, anthrax LF, and
Botulinum neurotoxin A light chain (BoNT/ALC) (14,25,26).
The assays employ recombinant fusion proteins consisting of a
protease substrate sequence (peptide with cleavage site) fused
at one end with a biotinylated attachment sequence and at the
other with GFP. The substrate fusion proteins are attached to
color-coded streptavidin microspheres via the biotin moiety
and protease activity is detected as a loss of microsphere GFP
fluorescence intensity, resulting from cleavage of bound sub-
strate (Supporting Information Fig. 4a). To adapt the protease
assay to 1,536-well plates, we reduced assay volumes from the
original 20–25 to 10 ll by concentrating assay components as
above. To two plates, we separately dispensed the mixtures of
proteases (LF and BoNT/ALC) and color-coded microspheres
bearing GFP fusion proteins (LF substrate, BoNT/ALC sub-
strate and a protein resistant to both proteases). We used a
1,536 pintool set to add 1,993 test compounds from the Mo-
lecular Libraries Small Molecule Repository (MLSMR) Valida-
tion Set (100 nL/well). The plates were incubated overnight on
the plate rotator to allow protease reactions to go to comple-
tion and processed the following day. Detailed results of the
compound screen, which also evaluated an additional protease
and microsphere-bound substrate in each well, will be
reported separately (PubChem Summary AIDs 566467,
566469, and 566470, updated at the completion of each
screening stage); however, we took the opportunity to assess
the repeatability of results by processing each plate three times
in succession.
From 1,492 wells on each plate, the mean, SD, and
corresponding CV were determined for the three sequential
measurements of median green fluorescence intensity of
each microsphere set in the well. In histograms plotting the
distribution of CVs for each set, the 95th percentiles ranged
from 4.6% for LF substrate to 5.4% for BoNT/ALC sub-
strate (Fig. 3). Thus, 95% or more of the replicate measure-
ments for each bead set had CVs of \6%. For substrates
susceptible to protease cleavage, Z0 scores derived from
positive and negative control wells (eight of each per plate
segment) averaged 0.73 (LF) and 0.86 (BoNT/ALC) over
the 24 separate plate segment determinations (Figs. 3b and
c, eight segments of two plates evaluated three times each).
These results indicated that the same plate can be analyzed
up to three times with the expectation of consistently good
data quality and reproducibility.
Validation Against 384-Well Plate Data
Under the auspices of the NIH-sponsored Molecular
Libraries Screening Centers Network and Probe Production
Centers Network (MLSCN and MLPCN, respectively), the sin-
gle-cytometer HyperCyt system has been applied to the
screening of small molecules from the MLSMR in more than
18 campaigns ([40 separate biological targets) involving a di-
versity of cell- and microsphere-based assays. To date, our
flow cytometry screening has been exclusively performed in
384-well format. To validate the performance of the Cluster
Cytometer platform, we selected a microsphere-based assay
that had recently been screened in 384-well format. The assay
was designed to detect the inhibitors selectively targeting
GRK2, an enzyme implicated in cardiac failure (31). In the
HTS assay, a green fluorescent RNA aptamer is used in a dis-
placement assay to identify small molecules that bind to the
regions of the GRK2 kinase domain critical for activity (Fig.
4a). Biotin-GRK2 is bound to streptavidin microspheres so
that the microspheres become brightly fluorescent in the pre-
sence of the aptamer. Hit detection is based on a decrease in
microsphere fluorescence intensity that results when a test
compound disrupts aptamer binding to GRK2 (Fig. 4b and
http://pubchem.ncbi.nlm.nih.gov/assay/
assay.cgi?aid5488855).
When Cluster Cytometer HTS was performed in 1,536-
well format using the MLSMR Validation Set, 14 compounds
inhibited aptamer binding to GRK2 by 25% or more (Fig. 4b
and Table 2). Of these, seven inhibited similarly in two sepa-
rate HTS campaigns performed in the low-density, 384-well
plate format (Table 2, confirmed), first in a screen of the Vali-
dation Set (PubChem AID 488806) and subsequently in a
screen of the full MLSMR library in which most of the Valida-
tion Set compounds are represented (327,943 compounds,
PubChem AID 488847). There was one compound that had
activity in the two single-cytometer screens but not in the
Cluster Cytometer screen; however, it failed to inhibit in a fol-
low-up confirmation screen (PubChem AID 504451) and was
considered a false positive (Table 2, compound ID 448222).
There were four compounds that were apparent hits in the
Cluster Cytometer screen but not in the single-cytometer
screen. We interpreted these hits as likely false positives as the
compounds were consistently inactive in the single-cytometer
screens. We have not analyzed these compounds further. Thus,
HTS in high-density plate format with the Cluster Cytometer
HyperCyt platform detected all compounds in the Validation
Set for which activity had been previously confirmed using
our conventional single-cytometer HTS platform.
DISCUSSION
The concept of using multiple flow cytometers in parallel
has some precedence in the recent past, applied primarily as
an approach to boost throughput of cell isolation and purifi-
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cation operations by fluorescence-based cell sorting. An exam-
ple is the commercial use of banks of high-speed cell sorters
running continuously in parallel to separate X- and Y-chro-
mosomes bearing sperm for use by breeders of domestic ani-
mals (e.g., www.sexingtechnologies.com/). Cell-sorting flow
cytometers are now commercially available in which up to
four sorting modules can be packed into the footprint of one
traditional instrument and operated in parallel over remote
network connections to speed up the purification of rare cell
subpopulations (www.i-cyt.com). Our integrated, multiple
flow cytometer screening platform now extends the parallel
flow cytometry concept to speed up performance and analysis
of large numbers of discrete biological experiments involving
cell and particle suspensions.
We have found cluster cytometry to offer a number of
benefits as compared to the alternate approach of operating
four separate flow cytometry screening platforms in parallel.
(1) Screening lab space requirement is significantly reduced.
(2) The close proximity of cytometers and sample delivery sys-
tems makes it more practical for the screening process to be
effectively implemented and monitored by a single operator.
(3) Synchronization of sample processing by the four cyt-
ometers facilitates automated ‘‘just-in-time’’ analysis of
screening assay data. In practice, we routinely produce a com-
plete analysis of the screening data for each plate (Z0, hit fre-
quency, number of cells/well, etc.) within the 10–12 min time
required to process the next plate. This allows rapid detection
of problems that might not be obvious by visual inspection so
that they can be quickly fixed. Affected plates are then placed
back on the rotating suspension system for later reanalysis. (4)
There is a single point of plate introduction rather than four
separate locations, more efficient for interfacing with an auto-
mated plate transport system. (5) There is flexibility of operat-
ing modes. The platform can be easily switched to run 1, 2, 3,
or 4 flow cytometers at a time and can accommodate micro-
plates of various well configurations (e.g., 96, 384, 12, 24,
etc.).
A potential disadvantage of the cluster cytometer
approach would be the consequences of a malfunctioning flow
cytometer or autosampler. One possible solution for accom-
modating cytometer failure would be to switch to two-cytom-
eter operating mode and process the two halves of a 1,536-well
plate in parallel. However, the modularity and moderate cost
of the Accuri C6 flow cytometer lends feasibility to an alter-
nate solution: having a backup unit available that can be
quickly swapped for a malfunctioning unit in the event of an
instrument problem that resists quick diagnosis and repair.
We have shown this to work in practice when the red laser on
one of the cytometers failed in the middle of a major screening
operation. It took only  15 min to swap in a backup unit to
allow successful completion of the screen. We also have a
backup autosampler (considerably less expensive than a flow
cytometer) that can be swapped for the original in  15 min
in the event, rare in our experience, and that the robotic sam-
ple handling component might fail. Thus, with appropriate
backup infrastructure recovery from failure has similar time
requirements whether operating in cluster or single-cytometer
mode.
An important issue for the cluster cytometer approach
was the need to evaluate equivalency of fluorescence responses
between flow cytometers and to have methods to correct for
potential interunit variability. In this study, we used calibra-
tion standard microspheres to evaluate FITC fluorescence
response equivalency of the cytometers. All showed linear flu-
orescence response profiles with parallel but offset regression
lines, an indication that there were differences in fluorescence
response sensitivity reflecting the ability to resolve dim fluo-
rescence in the FITC channel (Fig. 2e). It was expected that
Table 2. Validation of hit detection in HTS
INHIBITION OF APTAMER-30-FAM BINDING (%)
RESULTS IN 384-WELL HTS COMPOUND ID AIDA 488806 AID 488847 AID 504451 1,536-WELL HTS
Confirmed (All[25%) 16195270 92 88 94
6763 67 28 88
1780 62 50 55
460749 45 34 66
5702697 39 89 66
646406 34 47 29
6420073 92 NDb 99
False positive (One\25% ) 2957802 86 11 75
906542 61 0 82
2827740 33 0 38
448222 66 30 1 0
Negative (All\25%) 2936792 2 4 98
1522903 0 0 97
104871 5 2 57
12035 5 2 52
a PubChem assay ID for 384-well plate HTS results.
b ND, Not done.
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transformation of all fluorescence response data to the MESF
scale would suffice to ensure equivalency. This was indeed the
case for microsphere FITC fluorescence results (Supporting
Information Fig. 5). However, extended analysis of cell fluores-
cence data from control wells in the FPR ligand-binding assay
clearly showed that there were other sources of variability such
as putative plate position effects that may not have been at-
tributable to instrument performance differences. These con-
tributed to apparent disparities between cytometers that could
not be entirely resolved by MESF transformation (Supporting
Information Fig. 5). We conclude that a more robust method
for achieving quantitatively comparable results is to include
control wells in common for each cytometer that define assay
response limits (e.g., maximum and minimum response),
graded response output levels (e.g. different concentrations of
a response modulating chemical) or other response level
benchmarks. Fluorescence data from these wells can then serve
as a basis for normalizing results individually for each cytome-
ter to a common scale suitable for crosscomparison such as %
inhibition, % response relative to a control source of cells, %
response relative to a curve produced by a control chemical,
and so on. The same considerations apply for any fluorescence
channel in which the making of quantitative fluorescence
response comparisons is of interest. If compensation is
required to correct for fluorescence spillover between chan-
nels, common compensation controls are used to set up the
cytometers to produce similar results prior to sample process-
ing. Common assay control wells are then used to normalize
results postanalysis. In the cluster cytometry approach, as in
any studies involving a collection of flow cytometers running a
common assay (e.g., multi-institutional collaborations), the
low end of fluorescence intensity amenable to analysis will be
governed by the least sensitive instrument. An advantage of
the cluster approach is that all flow cytometers are evaluated
in parallel under the same experimental conditions so that
limiting conditions can be rapidly and unambiguously identi-
fied.
The present results demonstrate that bioassays involving
both cell and microsphere suspensions can be successfully per-
formed and analyzed in high-density, 1,536-well format with
robustness in quality and repeatability critical for the HTS
environment. Since the completion of these pilot studies, the
Cluster Cytometer HyperCyt platform has been successfully
Figure 3.
Figure 3. Data acquisition and analysis repeatability. A protease
inhibition assay screen was performed in which two 1,536-well
plates were sequentially processed three times each to determine
repeatability of fluorescence measurements. Wells contained
three color-coded bead sets to which were attached a protease re-
sistant substrate or substrates selectively cleaved by B. anthracis
LF or C. botulinum neurotoxin A light chain (BoNT/ALC). All wells
except negative control wells contained a mixture of LF and
BoNT/ALC proteases in the presence or absence of small-mole-
cule test compounds. Substrates were labeled with GFP so that
cleavage by protease resulted in a decrease of microsphere green
MFI. Illustrated are the distributions of CV of the replicate MFI
determinations from 1,492 wells for (a) protease resistant, (b) LF
sensitive, and (c) BoNT/ALC-sensitive substrates. CV 5 100 3 MFI
SD/MFI mean. Indicated in each panel are the mean, SD, and 95th
percentile of the CV distribution. For protease sensitive substrates
(b and c), Z0 scores were calculated from MFI determinations in
the presence and absence of protease (control wells to which
compounds were not added). Indicated are the mean, SD, and
range of the 24 Z0 scores (four-plate segments from two plates
measured three times each). Details of flow cytometry gating
strategy and an assay schematic are shown in Supporting
Information Figure 4.
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used for HTS of a multiplexed assay to detect the inhibitors of
three proteases (referenced above) against the full MLSMR
library of more than 350,000 small molecules (PubChem Sum-
mary AIDs 566467, 566469, and 566470). After a preliminary
series of smaller shakedown runs, we routinely screened more
than 51,000 compounds (60,000 wells when including controls
and rinse wells) per day.
This technology complements the capabilities of ima-
ging-based platforms that have been successfully used for high
content, high-throughput analyses of surface-attached cells.
Moreover, it is uniquely positioned to augment rapidly
expanding suspension array and fluorescent cell barcoding
technologies in which as many as 100 bioassays are performed
in a single well (32,33). We have successfully implemented a
number of such multiplexed assays for HTS campaigns in sin-
gle flow cytometer, 384-well plate format. Recently documen-
ted examples include a fluorescently ‘‘barcoded’’ five-plex of
cell strains from the Yeast-GFP collection to probe Target-of-
Rapamycin signaling pathways (34) (PubChem AID 1867)
and a six-plex of color-coded microspheres to probe BCL-2
family protein binding interactions (35,36) (PubChem AID
1908). A relatively modest 10-plex bioassay performed in
high-density format can be expected to produce over 15,000
distinct and quantitative experimental measurements in\11
min from a single 1,536-well plate. It seems likely that large-
scale bioassay multiplexing capabilities will prove a useful tool
for probing complex systems of biomedical importance such
as signaling networks, drug selectivity, crossreactivity, and so
on. Of additional importance is our demonstration that such
versatility can be achieved with relatively low cost but power-
ful, small-footprint flow cytometers that have only recently
become commercially available. The advent of the low-cost
personal computer enabled the implementation of parallel
computing systems as an affordable approach for resolving
large-scale computational problems. We anticipate that a simi-
lar trend will lead to cluster cytometry as a practical approach,
affordable to a broader segment of the worldwide research
community, for addressing large-scale studies of biological
complexity. Parallel-channel, chip-based microfluidic sorting
systems are currently in development that promise to further
extend the throughput capabilities of parallel flow cytometry
(e.g., www.cytonome.com), and it will be of great interest to
see how performance, versatility, failure-mode recovery
options, and costs of such systems will compare with modular
systems such as reported here.
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